GlaxoSmithKline is a very large UK based pharmaceutical company with an excellent track record of delivering increased dividends to shareholders. In recent years it has been changing its strategy and reducing it's dependence on the pure pharmaceuticals business.
| Year | Amount | Change |
|---|---|---|
| 2006 | 48.0p | |
| 2007 | 53.0p |
10.4%
|
| 2008 | 57.0p |
7.5%
|
| 2009 | 61.0p |
7.0%
|
| 2010 | 65.0p |
6.6%
|
| 2011 | 70.0p |
7.7%
|
| 2012 | 74.0p |
5.7%
|
| 2013 | 78.0p |
5.4%
|
| 2014 | 80.0p |
2.6%
|
| 2015 | 80.0p |
0%
|
| 2016 | 80.0p |
0%
|
| 2017 | 80.0p |
0%
|
| 2018 | Login required | |
| 2019 | Login required | |
| 2020 | Login required | |
| Ex-Div Date | Pay Date | Year | Type | Frequency | Status | Amount |
|---|---|---|---|---|---|---|
| 05 May 2010 | 08 Jul 2010 | 2010 | Interim | Quarterly | Paid | 15p |
| 28 Jul 2010 | 07 Oct 2010 | 2010 | Interim | Quarterly | Paid | 15p |
| 27 Oct 2010 | 06 Jan 2011 | 2010 | Interim | Quarterly | Paid | 16p |
| 09 Feb 2011 | 07 Apr 2011 | 2010 | Final | Quarterly | Paid | 19p |
| 04 May 2011 | 07 Jul 2011 | 2011 | Interim | Quarterly | Paid | 16p |
| 03 Aug 2011 | 06 Oct 2011 | 2011 | Interim | Quarterly | Paid | 16p |
| 02 Nov 2011 | 05 Jan 2012 | 2011 | Interim | Quarterly | Paid | 17p |
| 15 Feb 2012 | 12 Apr 2012 | 2011 | Final | Quarterly | Paid | 21p |
| 09 May 2012 | 05 Jul 2012 | 2012 | Interim | Quarterly | Paid | 17p |
| 08 Aug 2012 | 04 Oct 2012 | 2012 | Interim | Quarterly | Paid | 17p |
| 14 Nov 2012 | 03 Jan 2013 | 2012 | Interim | Quarterly | Paid | 18p |
| 20 Feb 2013 | 11 Apr 2013 | 2012 | Final | Quarterly | Paid | 22p |
| 08 May 2013 | 11 Jul 2013 | 2013 | Interim | Quarterly | Paid | 18p |
| 07 Aug 2013 | 03 Oct 2013 | 2013 | Interim | Quarterly | Paid | 18p |
| 13 Nov 2013 | 09 Jan 2014 | 2013 | Interim | Quarterly | Paid | 19p |
| 19 Feb 2014 | 10 Apr 2014 | 2013 | Final | Quarterly | Paid | 23p |
| 14 May 2014 | 10 Jul 2014 | 2014 | Interim | Quarterly | Paid | 19p |
| 06 Aug 2014 | 02 Oct 2014 | 2014 | Interim | Quarterly | Paid | 19p |
| 06 Nov 2014 | 08 Jan 2015 | 2014 | Interim | Quarterly | Paid | 19p |
| 19 Feb 2015 | 09 Apr 2015 | 2014 | Final | Quarterly | Paid | 23p |
| 14 May 2015 | 09 Jul 2015 | 2015 | Interim | Quarterly | Paid | 19p |
| 13 Aug 2015 | 01 Oct 2015 | 2015 | Interim | Quarterly | Paid | 19p |
| 12 Nov 2015 | 14 Jan 2016 | 2015 | Interim | Quarterly | Paid | 19p |
| 18 Feb 2016 | 14 Apr 2016 | 2015 | Final | Quarterly | Paid | 23p |
| 18 Feb 2016 | 14 Apr 2016 | 2015 | Special | Irregularly | Paid | 20p |
| 12 May 2016 | 14 Jul 2016 | 2016 | Interim | Quarterly | Paid | 19p |
| 11 Aug 2016 | 13 Oct 2016 | 2016 | Interim | Quarterly | Paid | 19p |
| 03 Nov 2016 | 12 Jan 2017 | 2016 | Interim | Quarterly | Paid | 19p |
| 23 Feb 2017 | 13 Apr 2017 | 2016 | Final | Quarterly | Paid | 23p |
| 11 May 2017 | 13 Jul 2017 | 2017 | Interim | Quarterly | Paid | 19p |
| 10 Aug 2017 | 12 Oct 2017 | 2017 | Interim | Quarterly | Paid | 19p |
| 09 Nov 2017 | 11 Jan 2018 | 2017 | Interim | Quarterly | Paid | 19p |
| 22 Feb 2018 | 12 Apr 2018 | 2017 | Final | Quarterly | Paid | 23p |
| 10 May 2018 | 12 Jul 2018 | 2018 | Interim | Quarterly | Paid | 19p |
| 09 Aug 2018 | 11 Oct 2018 | 2018 | Interim | Quarterly | Paid | 19p |
| 15 Nov 2018 | 10 Jan 2019 | 2018 | Interim | Quarterly | Declared | 19p |
| Login | Login | 2018 | Final | Quarterly | Forecast | Login |
| Login | Login | 2019 | Interim | Quarterly | Forecast | Login |
| Login | Login | 2019 | Interim | Quarterly | Forecast | Login |
| Login | Login | 2019 | Interim | Quarterly | Forecast | Login |
| Login | Login | 2019 | Final | Quarterly | Forecast | Login |
| Login | Login | 2020 | Interim | Quarterly | Forecast | Login |
| Login | Login | 2020 | Interim | Quarterly | Forecast | Login |
| Login | Login | 2020 | Interim | Quarterly | Forecast | Login |
| Login | Login | 2020 | Final | Quarterly | Forecast | Login |
| Login | Login | 2021 | Interim | Quarterly | Forecast | Login |
We start 2015 focused on priorities critical to GSK's performance this year. These include completion of the proposed major 3-part transaction with Novartis, improved commercialisation of new products and progression of our mid-stage R&D pipeline, capitalising on product supply resumption in our Consumer business and execution of our pharmaceutical restructuring programme.
Read more
First quarter dividend +6% to 19p. Share buy backs of £1-2 billion targeted during 2014
Read more
GSK announces Q2 core EPS growth of 4% and dividend of 18p
Read more
GSK delivers2012 core EPS of 112.7p and returns £6.3 billion to shareholders
Read more
Ok. It is big Pharma time. I am going to use the DividendMax tool to select on sector and then use other criteria to try and whittle down to the best Pharma dividend stock out there and that will become my dividend of the week.
Read more
This article which appeared in the Saturday edition of the FT on 27th October talks about investors chasing dividends. It is a good read and vindicates our stance that the only reason to invest in equities at the present time is for Dividends.
Read more
Try the real thing now:
You currently don't have access this feature, however you can preview the functionality.
This is a fully-functional demo intended to showcase the usefulness of this product using old data.
By proceeding you acknowledge that shown here is old data for demonstration purposes only.
To immediately activate your free account and see the live data you can log in with Facebook or LinkedIn:
Risk Warning / Disclaimer Our content ≠advice
All DividendMax content is provided for informational and research purposes only and is not in any way meant to represent trade or investment recommendations.
We accept no liaibility whatsoever for any decision made or action taken or not taken. Nothing shall substitute for the independent investigations and sound judgement of our users.
DividendMax’s sister product is Woodseer through our partnership with EDI
DividendMax.com is owned and operated by Investment Tools Ltd. Company registration number 7783804
DividendMax partners
